# Randomized Clinical Trial, Open, Multicenter Parallel, no Suspension Inferiority Prophylactic Treatment With Valganciclovir in Kidney Transplant CMV-seropositive Cellular Immunity to Develop CD8 + CMV-specific Treatment After Induction Thymoglobulin.

> **NCT03123627** · PHASE3 · COMPLETED · sponsor: **Maimónides Biomedical Research Institute of Córdoba** · enrollment: 150 (actual)

## Conditions studied

- Kidney Transplant Infection

## Interventions

- **DRUG:** New profilaxis
- **DRUG:** Profilaxis recommended

## Key facts

- **NCT ID:** NCT03123627
- **Lead sponsor:** Maimónides Biomedical Research Institute of Córdoba
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-23
- **Primary completion:** 2019-10-21
- **Final completion:** 2019-10-21
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2021-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03123627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03123627, "Randomized Clinical Trial, Open, Multicenter Parallel, no Suspension Inferiority Prophylactic Treatment With Valganciclovir in Kidney Transplant CMV-seropositive Cellular Immunity to Develop CD8 + CMV-specific Treatment After Induction Thymoglobulin.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03123627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*